ArticlePharmacogenomics2018
Attempted validation of 44 reported SNPs associated with tacrolimus troughs in a cohort of kidney allograft recipients.
Article in Pharmacogenomics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Polymorphisms inFrontiers in pharmacology · 2025Pooled it
- Introduction to Pharmacogenomics: Role of the Histocompatibility and Immunogenetics Laboratory in Personalised Medicine-Current Status and Future Prospects.International journal of immunogenetics · 2026Review
- Integrating pharmacogenetic and clinical factors to predict the C0/D/W-based tacrolimus phenotype in kidney transplantation.Frontiers in pharmacology · 2026Article
- Challenges in optimizing tacrolimus therapy in patients treated with rifampin: A case series.British journal of clinical pharmacology · 2025Article
- Non-HLA Genetics and Application to Living Donor Candidates.Current transplantation reports · 2025Article
- Association Study of OATP1B3 Polymorphisms on Hepatic Uptake and Drug-Drug InteractionACS omega · 2025Article
- Unveiling the heritability of selected unexplored pharmacogenetic markers in the Saudi population.Frontiers in pharmacology · 2025Article
- Pharmacogenetics association with long-term clinical evolution in a kidney transplant patients cohort.Current research in pharmacology and drug discovery · 2025Article
- Impact ofFrontiers in pharmacology · 2025Article
- Tacrolimus pharmacokinetics are influenced by CYP3A5, age, and concomitant fluconazole in pediatric kidney transplant patients.Clinical and translational science · 2023Article
- Evaluation of limited-sampling strategies to calculate AUCFrontiers in pharmacology · 2023Article
- Association betweenBrain sciences · 2022Article
- The impact of IL-10 and CYP3A5 gene polymorphisms on dose-adjusted trough blood tacrolimus concentrations in early post-renal transplant recipients.Pharmacological reports : PR · 2021Article
- CYP3A5 and PPARA genetic variants are associated with low trough concentration to dose ratio of tacrolimus in kidney transplant recipients.European journal of clinical pharmacology · 2021Article
- Functional CYP3A variants affecting tacrolimus trough blood concentrations in Chinese renal transplant recipients.The pharmacogenomics journal · 2021Article
- Genetic Polymorphisms Affecting Tacrolimus Metabolism and the Relationship to Post-Transplant Outcomes in Kidney Transplant Recipients.Pharmacogenomics and personalized medicine · 2021Article
- CYP3A5 and UGT1A9 Polymorphisms Influence Immunosuppressive Therapy in Pediatric Kidney Transplant Recipients.Frontiers in pharmacology · 2021Article
- Impacts of High Intra- and Inter-Individual Variability in Tacrolimus Pharmacokinetics and Fast Tacrolimus Metabolism on Outcomes of Solid Organ Transplant Recipients.Journal of clinical medicine · 2020Article
- Influence of Germline Genetics on Tacrolimus Pharmacokinetics and Pharmacodynamics in Allogeneic Hematopoietic Stem Cell Transplant Patients.International journal of molecular sciences · 2020Article
- Tacrolimus troughs and genetic determinants of metabolism in kidney transplant recipients: A comparison of four ancestry groups.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2019Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
aimMultiple genetic variants have been associated with variation in tacrolimus (TAC) trough concentrations. Unfortunately, additional studies do not confirm these associations, leading one to question if a reported association is accurate and reliable. We attempted to validate 44 published variants associated with TAC trough concentrations. MATERIALS &
methodsGenotypes of the variants in our cohort of 1923 kidney allograft recipients were associated with TAC trough concentrations.
resultsOnly variants in CYP3A4 and CYP3A5 were significantly associated with variation in TAC trough concentrations in our validation.
conclusionThere is no evidence that common variants outside the CYP3A4 and CYP3A5 loci are associated with variation in TAC trough concentrations. In the future rare variants may be important and identified using DNA sequencing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.